Australia's most trusted
source of pharma news
Posted 18 February 2025 PM
More than half the patients enrolled in a Phase 1b trial of a combination treatment for people who have failed multiple lines of therapy for a blood cancer have achieved a complete response.
Sydney-based Imugene is running the trial of its off-the-shelf CAR T therapy azercabtagene zapreleucel (azer-cel) in combination with chemotherapy and interleukin 2 in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in which four out of the seven enrolled have achieved a complete response.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.